Synopsis: Caplin Point Laboratories Limited, a small-cap pharma firm, is trading at a 34.36% discount from its 52-week high, attracting attention due to consistent growth, strong returns, and upcoming expansion plans.
This Small-cap Pharma Stock, engaged in manufacturing, developing, and exporting generic pharmaceuticals, including formulations, injectables, and softgel capsules across regulated and emerging global markets, is in focus after the stock is currently trading at a discount of 34.36 percent.
With a market…
